Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products

Dana Goldman and Darius Lakdawalla

Chapter Chapter Thirteen in Handbook of Health Economics, 2011, vol. 2, pp 825-872 from Elsevier

Abstract: Intellectual property rights are viewed as essential to medical innovation, but very often involve social costs due to patent monopolies and other inefficiencies. We review the positive theory of innovation in health care, as it relates to the determination of innovation demand and supply. The positive theory is related to a host of competing normative models of intellectual property, including patent races, cumulative or sequential innovation, and the implications of health insurance. We also discuss how intellectual property can be used to solve a variety of production externalities that afflict health care, including network externalities, underprovision of marketing, and inefficient provision of diagnostic information. Finally, we discuss novel approaches to protecting intellectual property, including rewards, innovation subsidies, and publicly provided health insurance.

Keywords: innovation; patents; pharmaceuticals; medical devices (search for similar items in EconPapers)
JEL-codes: I12 I18 O3 (search for similar items in EconPapers)
Date: 2011
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/B978044453592400013X
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:heachp:2-825

DOI: 10.1016/B978-0-444-53592-4.00013-X

Access Statistics for this chapter

More chapters in Handbook of Health Economics from Elsevier
Bibliographic data for series maintained by Catherine Liu ().